Immunome (IMNM) Income towards Parent Company (2019 - 2026)
Immunome (IMNM) posted Income towards Parent Company of -$244.2 million for Q1 2026, down 234.11% on a QoQ basis from -$73.1 million in Q4 2025, and down 443.98% year-over-year from $71.0 million in Q1 2025.
Immunome (IMNM) Income towards Parent Company (2019 - 2026) Analysis & Trends
Immunome's Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$244.2 million for Q1 2026.
- Quarterly Income towards Parent Company fell 443.98% year-over-year to -$244.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$489.6 million (down 48.11% YoY) and the FY2025 annual result came in at -$404.8 million, up 1.88% from the prior year.
- Income towards Parent Company was -$244.2 million for Q1 2026 at Immunome, down from -$73.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$4.6 million in Q1 2023 and bottomed at -$244.2 million in Q1 2026.
- A 5-year average of -$66.2 million and a median of -$70.3 million in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2024 — Income towards Parent Company slumped 2796.5% — and 2025, when it surged 66.09%.
- Immunome's Income towards Parent Company stood at -$8.1 million in 2022, then plunged by 1071.79% to -$94.7 million in 2023, then advanced by 12.04% to -$83.3 million in 2024, then climbed by 12.21% to -$73.1 million in 2025, then sank by 234.11% to -$244.2 million in 2026.
- Business Quant data shows IMNM's Income towards Parent Company at -$244.2 million in Q1 2026, -$73.1 million in Q4 2025, and -$101.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Immunome | 2.51 Bn | 1.93 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -244.25 Mn |
| Dec 31, 2025 | -73.10 Mn |
| Sep 30, 2025 | -101.90 Mn |
| Jun 30, 2025 | -70.30 Mn |
| Mar 31, 2025 | -44.90 Mn |
| Dec 31, 2024 | -83.27 Mn |
| Sep 30, 2024 | -116.13 Mn |
| Jun 30, 2024 | -86.23 Mn |
| Mar 31, 2024 | -132.40 Mn |
| Dec 31, 2023 | -94.67 Mn |
| Sep 30, 2023 | -15.83 Mn |
| Jun 30, 2023 | -16.07 Mn |
| Mar 31, 2023 | -4.57 Mn |
| Dec 31, 2022 | -8.08 Mn |
| Sep 30, 2022 | -11.93 Mn |
| Jun 30, 2022 | -10.73 Mn |
| Mar 31, 2022 | -11.75 Mn |
| Dec 31, 2021 | -7.84 Mn |
| Sep 30, 2021 | -7.72 Mn |
| Jun 30, 2021 | -26.04 Mn |